Carl Danzig, MD
Ophthalmology · Pompano Beach, FLNPI 1619137320
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Astellas Pharma US Inc at 27.9% of the total. 2025 is the largest year on record at $150,110, 3.3 times the $45,559 reported in 2019. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 489 payments — averaging $989.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$135K
- Genentech USA, Inc.$102K
- Ocular Therapeutix, Inc.$75K
- Hoffmann-la Roche Limited$39K
- Genentech, Inc.$37K
- Novartis$36K
- plus $61K from 25 others
Across 784 payments — averaging $6199.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.6M
- Novartis$674K
- Ocular Therapeutix, Inc.$499K
- Bayer$400K
- Roche TCRC, Inc.$351K
- Regeneron$97K
- plus $214K from 7 others
What the payments were for
- Consulting fees$244,49151%
- Speaking & faculty fees$191,53040%
- Travel & lodging$27,3616%
- Food & beverage$20,3964%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 100 | $135,214 |
| Genentech USA, Inc. | 97 | $101,568 |
| Ocular Therapeutix, Inc. | 74 | $74,883 |
| Hoffmann-la Roche Limited | 5 | $38,583 |
| Genentech, Inc. | 36 | $36,523 |
| Novartis | 40 | $36,443 |
| Regeneron Healthcare Solutions, Inc. | 26 | $20,784 |
| AbbVie(2 entities) | 27 | $15,708 |
| Astellas Pharma Global Development | 7 | $5,241 |
| F. Hoffmann-la Roche AG | 3 | $3,632 |
| Apellis Pharmaceuticals, Inc. | 10 | $3,574 |
| Alimera Sciences, Inc. | 18 | $2,265 |
| Dutch Ophthalmic, USA | 1 | $2,250 |
| Samsung Bioepis Co., Ltd. | 2 | $1,663 |
| Heidelberg Engineering, Inc. | 1 | $1,500 |
| Thrombogenics, Inc. | 1 | $1,250 |
| Regeneron | 15 | $898 |
| Roche TCRC, Inc. | 2 | $709 |
| Harrow Eye, LLC | 4 | $343 |
| Aerie Pharmaceuticals, Inc. | 4 | $135 |
| ANI Pharmaceuticals, Inc. | 3 | $109 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $103 |
| Astellas US LLC | 1 | $95 |
| Eyepoint US, Inc. | 2 | $58 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| Topcon Healthcare, Inc. | 1 | $50 |
| Notal Vision, Inc. | 1 | $49 |
| Biotissue Holdings Inc. | 2 | $46 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
| Biogen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$133,738
- VABYSMO$97,288
- BEOVU$27,673
- EYLEA$19,978
- Lucentis$13,497
- Non-Covered Product$9,266
- SUSVIMO$6,856
- EVA Ophthalmic Surgical System$2,250
- Iluvien$1,912
- OZURDEX$1,789
- YUTIQ$1,519
- Spectralis$1,500
- Jetrea$1,250
- DEXTENZA$1,243
- E301$713
- EYLEA HD$479
- XIIDRA$178
- IHEEZO$150
- BUPARLISIB$122
- enVista MX60 IOL$103
How this compares
$483,777 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VabysmoFaricimab-Svoa | 452 | $1,401,328 |
| EyleaAflibercept | 167 | $451,933 |
| Eylea HdAflibercept | 99 | $402,635 |
| IzervayAvacincaptad Pegol Sodium/Pf | 100 | $240,941 |
| LucentisRanibizumab | 19 | $40,580 |
| OzurdexDexamethasone | 11 | $16,387 |
| RocklatanNetarsudil Mesylat/Latanoprost | 32 | $12,183 |
| RestasisCyclosporine | 16 | $11,740 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $10,704 |
| ProlensaBromfenac Sodium | 21 | $8,142 |
| Alphagan PBrimonidine Tartrate | 13 | $5,360 |
| Prednisolone Acetate | 85 | $3,196 |
| Brimonidine Tartrate | 116 | $2,801 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,376 |
| Difluprednate | 23 | $2,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Vabysmo | $101,568 | $1,401,328452 claims |
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $20,784 | $854,568266 claims |
| Astellas Pharma US IncIzervay | $135,214 | $240,941100 claims |
| AbbVieOzurdex, Restasis, Combigan, Alphagan P | $15,708 | $44,19172 claims |
| Genentech, Inc.Lucentis | $36,523 | $40,58019 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $135 | $12,18332 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $103 | $8,14221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Pompano Beach
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.